

Carmelo Pozzo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9098449/carmelo-pozzo-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31
papers

810
citations

13
h-index

28
g-index

33
ext. papers

955
ext. citations

4.5
avg, IF

3.44
L-index

#	Paper	IF	Citations
31	Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis. <i>Internal and Emergency Medicine</i> , 2021 , 16, 1341-1356	3.7	3
30	Nutritional Support in Lung Cancer Patients: The State of the Art. <i>Clinical Lung Cancer</i> , 2021 , 22, e584-e594	4.9	8
29	Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study. <i>Nutrients</i> , 2021 , 13,	6.7	3
28	Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study). <i>Cancers</i> , 2021 , 13,	6.6	2
27	Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma. <i>World Journal of Gastrointestinal Surgery</i> , 2021 , 13, 885-903	2.4	2
26	A detailed analysis of the recurrence timing and pattern after curative surgery in patients undergoing neoadjuvant therapy or upfront surgery for gastric cancer. <i>Journal of Surgical Oncology</i> , 2020 , 122, 293-305	2.8	5
25	Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: A systematic review and meta-analysis. <i>Clinical Nutrition</i> , 2020 , 39, 2045-2054	5.9	36
24	Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. <i>Nutrients</i> , 2020 , 12,	6.7	6
23	Effects of nutritional interventions on nutritional status in patients with gastric cancer: A systematic review and meta-analysis of randomized controlled trials. <i>Clinical Nutrition ESPEN</i> , 2020 , 38, 28-42	1.3	20
22	The Facts about Food after Cancer Diagnosis: A Systematic Review of Prospective Cohort Studies. <i>Nutrients</i> , 2020 , 12,	6.7	6
21	What Chemotherapy Is Practicable in Aged Patients? 2018 , 331-337		
20	Preoperative therapy and long-term survival in gastric cancer: One size does not fit all. <i>Surgical Oncology</i> , 2018 , 27, 575-583	2.5	7
19	Pathologic complete response after neoadjuvant chemotherapy as a real surrogate endpoint of outcome for all breast cancer subtypes? Results of a single institution experience.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e11613-e11613	2.2	
18	ERCC1 induction after oxaliplatin exposure may depend on KRAS mutational status in colorectal cancer patient: preliminary data from liquid biopsy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11033-11033	2.2	
17	Emergency care in cancer patients: Data on 15,623 cases from a large volume single centre.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17577-e17577	2.2	
16	Resection of lung metastases from colorectal cancer: Analysis of outcome and prognostic factors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14556-e14556	2.2	
15	Potential role of IL-8 and eNOS polymorphisms in the outcome of bevacizumab-treated colorectal cancer patients: an exploratory analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e22015-e22015	2.2	

14	Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use. <i>Drugs</i> , 2013 , 73, 2003-15	12.1	40
13	Chance of cure following liver resection for initially unresectable colorectal metastases: analysis of actual 5-year survival. <i>Journal of Gastrointestinal Surgery</i> , 2013 , 17, 352-9	3.3	24
12	Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. <i>Quality of Life Research</i> , 2009 , 18, 853-61	3.7	29
11	Advances in neoadjuvant therapy for colorectal cancer with liver metastases. <i>Cancer Treatment Reviews</i> , 2008 , 34, 293-301	14.4	23
10	Recurrent disease four years after surgery and adjuvant chemotherapy. <i>Cancer Treatment Reviews</i> , 2008 , 34 Suppl 2, S8-11	14.4	2
9	Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?. <i>Oncologist</i> , 2008 , 13, 794-806	5.7	27
8	7-Year survival results of perioperative chemotherapy with epidoxorubicin, etoposide, and cisplatin (EEP) in locally advanced resectable gastric cancer: up-to-date analysis of a phase-II study. <i>Annals of Surgical Oncology</i> , 2008 , 15, 2146-52	3.1	11
7	Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2007 , 10, 104-11	7.6	26
6	Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. <i>Journal of Gastrointestinal Surgery</i> , 2007 , 11, 318-24	3.3	48
5	Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. <i>European Journal of Cancer</i> , 2006 , 42, 2212-21	7.5	404
4	Coronary artery spasm induced by capecitabine. <i>Journal of Cardiovascular Medicine</i> , 2006 , 7, 136-8	1.9	18
3	Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy. <i>Journal of Surgical Oncology</i> , 2005 , 89, 227-36; discussion 237-8	2.8	28
2	Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies. <i>Cancer</i> , 1998 , 82, 1460-7	6.4	28
1	5-Fluorouracil (FU) with folinic acid (FA) and mitomycin C (MMC) in the adjuvant treatment of colorectal carcinoma. Part I. Evaluation of toxicity. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1991 , 8, 69-73		2